Voyager Therapeutics, Inc. Cash Flow Statement
VYGR|11 years of annual SEC 10-K data (FY2015-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 11 fiscal years. All figures from audited SEC 10-K filings.
Voyager Therapeutics, Inc. generated $78M in operating cash flow and $75M in free cash flow in FY2025. Free cash flow margin was 29.9% of revenue.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 0.34 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $132.3M | -$46.4M | -$71.2M | $36.7M | -$43.6M | -$88.3M | -$70.7M | -$40.2M | -$29.7M | -$16.3M | -$3.8M |
| Depreciation & Amortization | $4.4M | $6.2M | $5.2M | $3.8M | $2.8M | $2.1M | $1.6M | $612.0K | $600.0K | $184.0K | $184.0K |
| Operating Cash Flow | $77.9M | -$12.5M | -$53.5M | -$96.7M | $48.7M | -$15.9M | -$61.4M | -$42.5M | $41.3M | -$11.9M | -$2.7M |
| Capital Expenditures | $3.3M | $2.5M | $1.6M | $12.1M | $7.7M | $4.3M | $4.0M | $5.0M | $1.0M | $3.0M | $3.0M |
| Free Cash Flow | $74.7M | -$15.0M | -$55.1M | -$108.8M | $40.9M | -$20.2M | -$65.3M | -$47.5M | $40.3M | -$14.9M | -$5.7M |
| FCF Margin | 29.9% | -36.7% | -147.4% | -63.6% | 39.2% | -265.0% | -644.7% | -334.1% | 232.3% | -86.0% | -221.8% |